Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: Is it a really good end point?

Journal of Clinical Oncology

Volumn 27, Issue 28, 2009, Pages

  Montagnani, Francesco ^a   Migali, Cristina ^b   Fiorentini, Giammaria ^a  

^a San Giuseppe Hospital   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CORRELATION COEFFICIENT; DRUG EFFICACY; HUMAN; LETTER; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; BIOASSAY; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; METHODOLOGY; NOTE; PATHOLOGY; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; NEOPLASM METASTASIS; REGRESSION ANALYSIS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 70350433282     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.1050     Document Type: Letter

References (9)

1. Mancuso MR, Davis R, Norberg SM, et al: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621, 2006
2. Cacheux W, Boisserie T, Goldwasser F, et al: Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19:1659-1661, 2008
3. Tang PA, Bentzen SM, Siu LL, et al: Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562-4568, 2007
4. Saltz LB, Clarke S, Cassidy J, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
5. Cassidy J, Clarke S, Salts L, et al: XELOX-1/NO16966, a randomized phase III trial of first-line XELOX compared with FOLFOX4 for patients with metastatic colorectal cancer (MCRC): Updated survival and tolerability results. American Society of Clinical Oncology Gastrointestinal Symposium, San Francisco, CA, January 15-17, 2009 (abstr 389)
6. Fuchs CS, Marshall J, Barrueco J, et al: Randomized controlled trial of irinotecan plus infusional, bolus, or oral, fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 25:4779-4786, 2007
7. Hochster HS, Hart LL, Hedrick E, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study. J Clin Oncol 26:3523-4697, 2008
8. Kabbinavar FF, Schulz J, Novotny WF, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005
9. Hurwitz H, Fehrenbacher L, Kabbinavar F, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 325:2335-2342, 2004